Showing 1 - 10 of 44
Persistent link: https://www.econbiz.de/10012264020
A large concern in U.S. opioid policy is whether supply side controls are effective at reducing the quantity of opioids prescribed, without harmful substitution. An unstudied way that policy targeted a major opioid through the federal Controlled Substance Act (CSA) was the August 2014 scheduling...
Persistent link: https://www.econbiz.de/10012481375
Persistent link: https://www.econbiz.de/10014474188
Persistent link: https://www.econbiz.de/10012055901
Persistent link: https://www.econbiz.de/10012627520
Drug control policy can have unintended consequences by pushing existing users to alternative, possibly more dangerous substances. Policies that target only new users may therefore be especially promising. Using commercial insurance claims data, we provide the first evidence on a set of new...
Persistent link: https://www.econbiz.de/10012867907
Drug control policy can have unintended consequences by pushing existing users to alternative, possibly more dangerous substances. Policies that target only new users may therefore be especially promising. Using commercial insurance claims data, we provide the first evidence on a set of new...
Persistent link: https://www.econbiz.de/10012479923
Prior work considers effects of prescribing restrictions on opioid use but not upstream implications for pharmaceutical marketing activities, despite the inordinate role many believe marketing played in the crisis. Our study proposes a stylized model of pharmaceutical payments and investigates...
Persistent link: https://www.econbiz.de/10012861727
Prior work considers effects of prescribing restrictions on opioid use but not upstream implications for pharmaceutical marketing activities, despite the inordinate role many believe marketing played in the crisis. Our study proposes a stylized model of pharmaceutical payments and investigates...
Persistent link: https://www.econbiz.de/10012480300
Persistent link: https://www.econbiz.de/10012129222